Jefferies Group set a $156.00 price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on the stock. Nomura upped their price target on shares of Alnylam Pharmaceuticals to $86.00 and gave the stock a sell rating in a research note on Friday. BMO Capital Markets dropped their price target on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an outperform rating on the stock in a research note on Friday. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $128.00 to $118.00 and set an equal weight rating on the stock in a research note on Friday. Leerink Swann upped their price target on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a market perform rating in a research note on Thursday, January 25th. Finally, B. Riley reaffirmed a buy rating and issued a $205.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $126.98.

Shares of Alnylam Pharmaceuticals (ALNY) opened at $117.30 on Friday. The stock has a market capitalization of $11,530.00, a price-to-earnings ratio of -21.68 and a beta of 2.68. Alnylam Pharmaceuticals has a 1-year low of $44.50 and a 1-year high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.10). The business had revenue of $37.90 million during the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 48.88%. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.32) EPS. sell-side analysts expect that Alnylam Pharmaceuticals will post -5.69 EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 30,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $5,639,435. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John Maraganore sold 74,000 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the transaction, the chief executive officer now directly owns 223,710 shares in the company, valued at $28,379,850.60. The disclosure for this sale can be found here. Insiders have sold 220,409 shares of company stock worth $28,667,017 over the last three months. Company insiders own 4.30% of the company’s stock.

Several large investors have recently modified their holdings of the company. Eaton Vance Management grew its position in shares of Alnylam Pharmaceuticals by 15.7% in the fourth quarter. Eaton Vance Management now owns 36,866 shares of the biopharmaceutical company’s stock valued at $4,684,000 after purchasing an additional 5,000 shares during the last quarter. Alexandria Capital LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $18,602,000. Suntrust Banks Inc. grew its position in shares of Alnylam Pharmaceuticals by 8.1% in the fourth quarter. Suntrust Banks Inc. now owns 9,944 shares of the biopharmaceutical company’s stock valued at $1,263,000 after purchasing an additional 746 shares during the last quarter. American International Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $255,000. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $353,000. 88.59% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/alnylam-pharmaceuticals-alny-given-a-156-00-price-target-at-jefferies-group/1862221.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.